Introduction
============

In patients with COPD, the diaphragm is chronically overloaded, which is more serious with increasing severity of the disorder. As a result, several adaptations occur, including a shift from fast, glycolytic, type II fibers to slow, oxidative, type I fibers ([@b18-copd-1-83]; [@b22-copd-1-83]). Furthermore, metabolic changes occur, resembling those that emerge after endurance training, such as an increase in oxidative capacity ([@b24-copd-1-83]; [@b13-copd-1-83]; [@b26-copd-1-83]). Mitochondrial function is enhanced in the diaphragm of patients with COPD ([@b29-copd-1-83]), as indicated by increases in the maximum rate of mitochondrial respiration and efficiency of the mitochondrial electron transport chain. This is considered to be beneficial, because these changes cause an increase in endurance capacity.

Despite this shift towards a more fatigue-resistant muscle, the majority of patients with severe COPD die from respiratory failure ([@b4-copd-1-83]). This respiratory failure may have multiple causes, including insufficient force production or insufficient endurance capacity of the respiratory muscles, or a combination of these factors. For example, [@b19-copd-1-83] observed reduced force-generating capacity in the diaphragm of COPD patients.

Anabolic steroids may be helpful in preventing respiratory failure. Clinical studies have mainly investigated the effect of treatment with anabolic steroids on muscle force-generating capacity. For example, it has been shown that treatment with nandrolone decanoate (ND) improved respiratory muscle function and exercise capacity after a pulmonary rehabilitation program in COPD patients using oral glucocorticosteroids ([@b8-copd-1-83]). Treatment with testosterone resulted in increases in quadriceps muscle strength and endurance with and without a resistance training program in COPD patients ([@b6-copd-1-83]). In this study, testosterone did not change respiratory muscle strength.

In animal models, the effects of anabolic steroid treatment on oxidative capacity in several skeletal muscles have been investigated. Controversy exists in the literature about the effect of anabolic steroids on mitochondrial function and associated endurance capacity. The effect of anabolic steroids on mitochondrial function seems to be dependent on fiber type, with fast-twitch fibers ([@b31-copd-1-83]) or aerobic muscle ([@b10-copd-1-83]) being most sensitive to an increase in oxidative capacity in rats.

For preventing respiratory failure, it is important to know if treatment with anabolic steroids results in increased respiratory muscle oxidative capacity and mitochondrial function, especially in emphysema. Therefore, we investigated whether administration of ND increased the activity of mitochondrial respiratory chain complexes in the diaphragm of emphysematous hamsters. For this purpose, we treated healthy and emphysematous hamsters with ND or placebo and determined the activity of several parts of the mitochondrial energy-generating system.

Methods
=======

Animals
-------

Male 40-week-old inbred Syrian golden hamsters (Elevage Janvier) with initial bodyweight \~100 g were used. The animals were randomly divided into normal (NH) and emphysematous (EH) groups. The study was approved by the Animal Experiments Committee of the University Medical Centre Nijmegen and performed according to the Dutch National Guidelines of Animal Care.

### Induction of emphysema

Under anesthesia of a mixture of 2.5% isoflurane and N~2~O and (1:2), saline (NH) or porcine pancreatic elastase (18 U/100 g O~2~ bodyweight \[[@b28-copd-1-83]\] \[EPC, Owensville, MI, USA\] in 0.50 mL normal saline) was instilled intratracheally, as described in detail previously ([@b20-copd-1-83]; [@b39-copd-1-83]; [@b38-copd-1-83]).

### Determination of degree of emphysema

When the animals were killed the lungs were removed for measurement of the lung volume by fluid displacement to evaluate the extent of emphysema.

### Anabolic steroid administration

Fifty-two weeks after induction of emphysema, the normal hamsters and emphysematous hamsters were divided into treated (ND) and nontreated (CON) groups. Hamsters in the treated groups were injected for 10 weeks with 2.5 mg/kg ND (Deca-Durabolin, NV Organon, Oss, The Netherlands) once a week intramuscularly. To obtain maximum effect, ND was administered in the maximum dose as recommended by the manufacturer for use in patients. Hamsters in the control groups were injected with saline for the same period. Groups were subdivided as follows: NH CON (n=9), EH CON (n=12), NH ND (n=10), and EH ND (n=14).

### General procedures

Sixty-two weeks after instillation the hamsters were anesthetized with pentobarbital sodium (Nembutal, 70 mg/kg intraperitoneally). A polyethylene cannula was inserted through a tracheotomy for mechanical ventilation with 100% O~2~. The diaphragm was quickly excised after combined laparotomy and thoracotomy and put immediately in ice-cold SETH buffer (0.25 mol/L sucrose, 2 mmol/L EDTA, 10 mmol/L Tris, 5× 10^4^ U heparin, pH 7.4).

Mitochondrial function
----------------------

### Homogenization procedure of muscle tissue

Diaphragm muscle was washed with fresh ice-cold SETH, and fat and connective tissue were disconnected. Tissue was cut in very small pieces of about 0.1 × 0.1 mm with the aid of a Sorvall TC2 tissue chopper with razor blade. Tissue was homogenized in fresh ice-cold SETH buffer (5%--10% w/v) with a Potter Elvehjem tissue homogenizer according to [@b12-copd-1-83]. Some100-μL samples of the crude homogenate were frozen immediately in liquid nitrogen and kept at −80°C for measuring protein content, cytochrome c oxidase and citrate synthase (CS). The rest of the crude homogenate was centrifuged for 10 minutes at 2°C at 600 × *g*. The 600 × *g* supernatant was frozen in 100-μL aliquots in liquid nitrogen and kept at −80°C for measuring protein content, CS activity, and activities of respiratory chain enzymes. CS activity was measured according to [@b35-copd-1-83] with minor modifications. Briefly, a sample of the 600 × *g* supernatant was diluted (1:1) with SETH buffer containing 0.5% Triton X-100. A 50-μL sample was incubated in a total volume of 1.0 mL containing 0.1 mol/L Tris, 0.1 mmol/L DTNB (5,5′-dithio bis(2-nitro)-benzoate), 0.3 mmol/L acetylcoenzyme-A, and 0.5 mmol/L oxaloacetic acid, pH 8.1. In the blank, oxaloacetic acid was omitted. Coenzyme-A production by CS was measured spectrophotometrically at 412 nm by measuring the reduction of DTNB. Protein concentration was measured according to [@b21-copd-1-83] with minor modifications.

### Incubations

Incubations for determination of the activity of succinate: cytochrome c oxidoreductase (SCC) were performed according to [@b11-copd-1-83] with minor modifications. Incubations for determination of complex III (C-III) and complex IV (C-IV) activity were performed according to [@b2-copd-1-83] and [@b7-copd-1-83], respectively. Activities of SCC, C-III, and C-IV were divided by CS activity for correction for mitochondrial content.

Serum testosterone levels
-------------------------

When the animals were killed, blood samples were taken from the abdominal aorta for serum testosterone concentration measurements. Serum testosterone was assessed by a ^3^H-radioimmunoassay (RIA) after prepurification by means of paper chromatography of ether extracts of the samples, including correction for procedural losses, as described previously ([@b36-copd-1-83]). To summarize briefly, before extraction ^3^H-testosterone was added to correct for procedural losses. After chromatography, radio chromatogram scanning identified the location of the testosterone zone; the zone was cut out and soaked in buffer. The recovered radioactivity was measured by liquid scintillation counting of an aliquot from the eluate. Subsequently, testosterone tracer and antiserum were added, and after incubation, free and bound tracers were separated by means of dextrane-coated charcoal. The antibody-bound radioactivity was assessed by liquid scintillation counting of the supernatant. The calculations were performed by special software designed for correction of the mass and radioactive contribution of the recovery tracer in the RIA. The detection limit was 3.5 pmol/L.

Statistical analysis
--------------------

Data are presented as mean ± standard error of the mean (SEM) when appropriate. Data were analyzed with SPSS for Windows, version 12.0.1 (SPSS, Chicago, IL, USA). A one-way ANOVA (analysis of variance) test and a Tukey post hoc test were used to determine if there were differences between the groups. A paired *t* test was used to determine differences within the groups before and after treatment. Significance was set at the 0.05 level.

Results
=======

Bodyweight
----------

Bodyweight was significantly lower in both emphysematous hamster groups than in normal groups before treatment (p \< 0.05). After treatment, bodyweight was significantly lower in the normal nandrolone-treated hamster group and the emphysematous nandrolone-treated group than before treatment (p \< 0.05). The results are shown in [Table 1](#t1-copd-1-83){ref-type="table"}.

Degree of emphysema
-------------------

Mean lung volume was significantly higher in the emphysematous hamster groups than in the normal groups (17.0 ± 0.5 mL vs 11.4 ± 0.5 mL; p \< 0.001), indicating that in the emphysematous groups emphysema was indeed induced. Furthermore, lung volume was higher in emphysematous nandrolone-treated than emphysematous control hamsters (p = 0.004). Lung volumes are presented in [Table 1](#t1-copd-1-83){ref-type="table"}.

Serum testosterone levels
-------------------------

Serum testosterone levels were equal in emphysematous and normal hamsters. After treatment with ND, serum testosterone levels in normal nandrolone-treated hamsters were significantly decreased compared with those of normal control hamsters and in emphysematous nandrolone-treated hamsters compared with emphysematous controls (p = 0.001 and p \< 0.001, respectively). Serum testosterone levels are presented in [Figure 1](#f1-copd-1-83){ref-type="fig"}.

Mitochondrial function
----------------------

The activity of CS, C-III, and C-IV was equal between the four treatment groups. The activity of SCC was not different between normal control hamsters and emphysematous controls. However, after treatment with ND, the activity of SCC was significantly higher in the diaphragm of normal hamsters than in that of emphysematous animals. The mitochondrial function results are presented in [Figures 2](#f2-copd-1-83){ref-type="fig"}--[5](#f5-copd-1-83){ref-type="fig"}.

Discussion
==========

This is the first study to investigate the effects of treatment with an anabolic steroid on the activity of mitochondrial respiratory chain complexes in the diaphragm of emphysematous hamsters. It shows that the activity of mitochondrial respiratory chain complexes in the diaphragm was not different between normal and emphysematous hamsters. Treatment with ND did not change the activity of mitochondrial respiratory chain complexes in either normal or emphysematous hamsters. However, in emphysematous animals ND treatment decreased the activity of SCC compared with ND treatment in normal hamsters. Mitochondrial content was not changed after ND treatment. Furthermore, bodyweight of hamsters treated with ND was decreased after treatment compared with initial values, and serum testosterone levels were significantly lower in animals treated with ND than in controls.

In mitochondria, energy is produced by the mitochondrial oxidative phosphorylation system, which is embedded in the mitochondrial inner membrane and comprises five enzyme complexes (I--V) and two electron carriers (coenzyme Q and cytochrome c) ([@b14-copd-1-83]; [@b32-copd-1-83]). The main function of the system is the coordinated transport of electrons and protons through the different complexes, which leads to the production of adenosine triphosphate (ATP) ([@b34-copd-1-83]). This ATP can be used for diverse cell functions, including contractions in skeletal muscle. In our study, we found that mitochondrial energy-generating capacity of the diaphragm was not changed after treatment with anabolic steroids, either in normal or emphysematous hamsters. This is in agreement with the results of [@b31-copd-1-83], who found that in rat extensor digitorum longus (EDL), but not in soleus muscle, mitochondrial function was enhanced after treatment with fluoxymesterone and meth-androstanolone, suggesting a higher sensitivity for anabolic steroid in fast-twitch (EDL) muscle. In the same study, the number of mitochondria was not changed after administration of anabolic steroids. In contrast, [@b10-copd-1-83] suggested that aerobic muscles such as soleus and diaphragm are more susceptible to an increase of mitochondrial capacity after nandrolone phenylpropionate treatment. [@b1-copd-1-83] showed an increase in mitochondrial volume in rat diaphragm after treatment with 19-nortestosterone. This is in agreement with the findings of [@b33-copd-1-83], who found an increase in cross-sectional areas of mitochondria after treatment with nandrolone phenylpropionate in mouse diaphragm.

Comparison with previous results is difficult, because different studies use different dose, species, duration of treatment, age, mode of administration, and activity level. These factors have been shown to influence the effects of anabolic treatment ([@b5-copd-1-83]; [@b1-copd-1-83]; [@b17-copd-1-83]; [@b25-copd-1-83]). For example, treatment of male rats with 19-nortestosterone in a low dose resulted in an increase in mitochondrial volume proportions in type I and intermediate fibers, whereas treatment with a high dose resulted in a less marked increase in mitochondrial volume proportions, particularly in intermediate fibers, suggesting that the response on anabolic steroids was lower in the high-dose group ([@b1-copd-1-83]). The variation in the abovementioned factors may explain the fact that the literature is very inconsistent about the effect of treatment with anabolic steroids on mitochondrial function.

Another finding in our study is that after treatment with ND, SCC activity per mitochondrion is decreased in the diaphragm of emphysematous compared with normal hamsters. SCC activity measures complexes II and III and the electron carrier coenzyme Q, which are located in the mitochondrial inner membrane ([@b23-copd-1-83]). Molano and colleagues reported decreased activity of enzymes in the mitochondrial inner membrane of rat liver after treatment with stanozolol and fluoxymesterone, but no change in CS activity, which is located in the matrix space. The authors suggested that anabolic-androgenic steroids could affect the mitochondrial membrane owing to their hydrophobic nature. In the same study, no change in C-IV activity was found after treatment with stanozolol and fluoxymesterone, suggesting that electron transport is disturbed in the electron transport chain before C-IV by these anabolic steroids ([@b23-copd-1-83]). However, in our study we did not find a decrease in C-III activity after treatment with ND. This discrepancy in findings may be due to the difference in tissue studied, namely hamster diaphragm in our study versus rat liver in the study of Molano and colleagues. Furthermore, in the latter study the anabolic steroids were administered orally, which produces a first-pass effect in the liver, where the enzyme activities were measured. A possible explanation for our finding that SCC activity is decreased in the diaphragm of emphysematous hamsters treated with ND is that perhaps this specific mitochondrial part is more susceptible to the effects of ND administration in more active muscles (as is the diaphragm in emphysema).

It has recently been shown that the maximum rate of mitochondrial respiration and the efficiency of the electron transport chain for ATP production are increased in the diaphragm of COPD patients ([@b29-copd-1-83]). The maximum respiratory rate of the mitochondria in the diaphragm of COPD patients was twice as high as in the diaphragm of control subjects. Endurance training elicits an increase in maximum respiratory rate of the mitochondria in human vastus lateralis muscle ([@b40-copd-1-83]). However, this increase is much less than that observed in the diaphragm of COPD patients ([@b29-copd-1-83]). The respiratory rate is dependent on the muscle investigated in rats varying from 9.6 μmol O~2~/min/g dry weight in soleus muscle to 32μmol O~2~/min/g dry weight in cardiac muscle ([@b9-copd-1-83]). This rate also seems to be dependent on species, because the maximum mitochondrial respiration rate reported by [@b29-copd-1-83] in human diaphragm was 5.28 μmolO~2~/min/g dry weight, whereas the maximum respiration rate in rat diaphragm averaged 12μmol O~2~/min/g dry weight ([@b9-copd-1-83]). Data on interventions eliciting changes in human diaphragmatic mitochondrial function are not available. Therefore, it can not be predicted if the increase in mitochondrial respiration as found by Ribera and colleagues could be augmented by an intervention.

The fact that in our study we did not find an increase in the activity of mitochondrial respiratory chain complexes after ND treatment, either in normal or emphysematous hamsters, implies that treatment with ND may not increase the endurance capacity of the diaphragm. This suggests that treatment with anabolic steroids may not be able to prevent respiratory failure. However, respiratory failure may also be caused by a decrease in inspiratory muscle force-generating capacity. The role of anabolic steroids in preventing this cause of respiratory failure in patients with COPD is contradictory. For example, [@b8-copd-1-83] found an increase in maximum inspiratory muscle strength after ND treatment in COPD patients (50 mg ND/2 weeks). The patients in this study performed a pulmonary rehabilitation program consisting of several endurance activities. Only in patients using oral glucocorticosteroids did ND treatment have an additional beneficial effect on respiratory muscle function above the effect of pulmonary rehabilitation. This effect of ND was not observed in patients who did not use oral glucocorticosteroids. This is in accordance with the results of [@b6-copd-1-83], who found no change in maximum inspiratory muscle strength after administration of testosterone in COPD patients who did not receive long-term oral corticosteroid treatment. The finding that in patients using corticosteroids ND treatment restores respiratory muscle function is in line with animal experimental studies ([@b37-copd-1-83], [@b38-copd-1-83]). In a rat model, treatment with ND prevented the loss of diaphragm force induced by long-term, low-dose methylprednisolone administration ([@b37-copd-1-83]). A subsequent study ([@b38-copd-1-83]) reported that ND was also able to prevent the loss of diaphragmatic function in emphysematous hamsters treated with long-term, low-dose methylprednisolone. These findings, combined with findings in the abovementioned studies ([@b8-copd-1-83]; [@b6-copd-1-83]), suggest that treatment with anabolic steroids alone might be useful for preventing respiratory failure only in patients receiving corticosteroids.

In our study, we found that bodyweight was decreased after treatment with ND. This is in agreement with other studies, finding decreased bodyweight in male rats after treatment with ND ([@b3-copd-1-83]). Circulating endogenic androgens may play a role. Surpassing the physiological level of androgens in males has been reported to result in depression of the natural production of testosterone ([@b30-copd-1-83]), downregulation of androgen-binding receptors ([@b27-copd-1-83]), decrease in appetite ([@b16-copd-1-83]), and a metabolic conversion to excess estradiol ([@b15-copd-1-83]). The natural production of testosterone is indeed decreased in ND-treated hamsters in our study, which is shown by lower serum testosterone levels in the ND groups.

In conclusion, this study shows that the activity of mitochondrial respiratory chain complexes in the diaphragm in both normal and emphysematous hamsters was equal, and that treatment with ND did not change this activity. In emphysematous hamsters, administration of ND decreased the activity of SCC compared with ND treatment in normal hamsters. Furthermore, we have shown that bodyweight of hamsters treated with ND was decreased after treatment compared with initial values, and that treatment with ND resulted in significantly lower serum testosterone levels in both normal and emphysematous hamsters. Taking all results together, our data do not support the use of anabolic steroids in preventing respiratory failure caused by fatigue of the diaphragm.
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![Activity of complex III (C-III) in the diaphragm.](copd-1-83f4){#f4-copd-1-83}

![Activity of complex IV (C-IV) in the diaphragm.](copd-1-83f5){#f5-copd-1-83}

###### 

Bodyweights and lung volumes (mean ± SEM)

                           NH CON (n = 9)   EH CON (n = 12)                                       NH ND (n = 10)                                     EH ND (n = 14)
  ------------------------ ---------------- ----------------------------------------------------- -------------------------------------------------- -----------------------------------------------------------------------------------------------
  Initial bodyweight (g)   141 ± 5          127 ± 4[a](#tfn1-copd-1-83){ref-type="table-fn"}      146 ± 3                                            131 ± 3[a](#tfn1-copd-1-83){ref-type="table-fn"}
  Final bodyweight (g)     144 ± 6          129 ± 4                                               140 ± 3[b](#tfn2-copd-1-83){ref-type="table-fn"}   121 ± 3[b](#tfn2-copd-1-83){ref-type="table-fn"}
  Lung volume (mL)         10.9 ± 0.5       15.7 ± 1.8[c](#tfn3-copd-1-83){ref-type="table-fn"}   12.2 ± 0.8                                         18.3 ± 2.6[c](#tfn3-copd-1-83){ref-type="table-fn"},[d](#tfn4-copd-1-83){ref-type="table-fn"}

p \< 0.05 EH vs NH.

p \< 0.05 before vs after treatment.

p \< 0.001 EH vs NH.

p \< 0.01 EH ND vs EH CON.

**Abbreviations:** CON, control group; EH, emphysematous hamster; NH, normal hamster; ND, nandrolone group.
